{"slug":"prostamax","seoKey":"prostamax","displayName":"Prostamax","codes":["KEDP"],"synonyms":["Lys-Glu-Asp-Pro","H-Lys-Glu-Asp-Pro-OH","lysyl-glutamyl-aspartyl-proline (the NLM MeSH supplementary concept entry term)","Prostomax","Простамакс (Russian spelling)"],"legalClass":"research_chemical","identifiers":{"cas":"473578-47-1","pubchemCid":9848296,"inchikey":"WUCUNGRTSFLCLI-XUXIUFHCSA-N","formula":"C20H33N5O9","molecularWeight":487.5,"sequence":"KEDP"},"approvals":[{"market":"US","status":"not_approved","date":"2026-06-17","note":"Not approved and not registered as a substance, and the only peptide of this series named in an enforcement letter. Four federal checks on 2026-09-16 returned no match: no drug label, no entry in the labelling database, no record in the substance registration system, which is why there is no substance code, and no nomination for the compounding bulks list, although short peptides are listed there. On 17 June 2026 the regulator named the substance in a warning letter to a research chemical seller as an unapproved new drug under section 505(a), stating that a research-use-only label does not change that status and that injectable products bypass key defences of the body. The product page named in the letter returned an error on 2026-09-16 and no close-out letter was found. One adverse event report carrying the name concerns a plant-based prostate supplement of the same name, not the peptide.","source":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wholesale-peptide-729447-06172026"},{"market":"EU","status":"not_approved","note":"No centralised marketing authorisation, no assessment report and no pharmacopoeial monograph. The register itself could not be queried on 2026-09-16 because the site answered with an authorisation error, so this is a negative finding drawn from the absence of any entry in every other authority database checked and from the absence of any clinical development programme; the trial registry returns nothing for this substance while a control query returns 755 studies. An injectable preparation of an unauthorised active substance is not lawfully marketable.","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=prostamax"},{"market":"DE","status":"not_approved","note":"Neither a national nor an EU marketing authorisation exists, so an injectable preparation is not a marketable medicinal product and may not be imported or dispensed. The substance is also not named in the schedule to the Anti-Doping Act; the full text was searched on 2026-09-16 for the trade name, the code and the sequence without a hit, while control searches for tesamorelin and ipamorelin do hit. The schedule has no catch-all position for peptides, so possession is not an offence under that provision. Sporting rules are unaffected by that. Unlike several sibling peptides of this series, there is no Russian capsule form, so the novel food question does not arise in practice.","source":"https://www.gesetze-im-internet.de/antidopg/anlage.html"},{"market":"UK","status":"not_approved","note":"No marketing authorisation known. The product register returned only the JavaScript shell of its search page on 2026-09-16, and the query for this substance and a control query for an approved active ingredient produced byte-identical responses of 122,696 characters each, so the negative finding could not be verified positively. It rests on the absence of any entry elsewhere and on the absence of any clinical development. Research chemical shops addressing British buyers offer the material openly nonetheless.","source":"https://products.mhra.gov.uk/search/?search=prostamax"},{"market":"AU","status":"not_approved","note":"Not named in the Poisons Standard; the full text of the June 2026 instrument was searched on 2026-09-16 for the trade name, the sequence and the Russian extract preparation without a hit. There is no generic peptide position in that instrument, and short peptides are listed by name where they are scheduled: control searches for pralmorelin and alanylglutamine both hit. Absence of a listing is not a clearance, and an injectable preparation not entered in the therapeutic goods register may not be supplied. The register itself was not programmatically queryable on that day.","source":"https://www.legislation.gov.au/F2026L00633/asmade"},{"market":"CA","status":"not_approved","note":"No marketing authorisation and no entry in the drug product database; the query for the trade name returned an empty result on 2026-09-16, while a control query for an authorised product returned its identification number, so the interface was working.","source":"https://health-products.canada.ca/api/drug/drugproduct/?lang=en&type=json&brandname=prostamax"},{"market":"CH","status":"not_approved","note":"No marketing authorisation known. No direct register query was possible on 2026-09-16: the authority's list page answered but carries its authorisation lists only as downloadable files, which were not evaluated. This is therefore a negative finding drawn from the absence of an authorisation in every market that could be checked and from the absence of any clinical development programme.","source":"https://www.swissmedic.ch/"}],"devStage":"preclinical","strongestEvidence":"animal","wada":{"status":"prohibited","section":"S0","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":["https://pubchem.ncbi.nlm.nih.gov/compound/9848296"],"lastVerified":"2026-09-16","version":"1.0","published":true,"locale":"en","title":"Prostamax: what the studies show, status and safety","summary":"Prostamax is a synthetic chain of four amino acids from a St Petersburg institute. Six publications mention it and not one describes a person taking it. Its prostate label traces back to the inventors' own patent, not to a study. In June 2026 the American regulator named it in a warning letter as an unapproved new drug.","updated":"2026-09-16","url":"https://mypep.app/peptides/prostamax"}